WO2022063317A1 - 稠合的三并环衍生物及其在药学上的应用 - Google Patents
稠合的三并环衍生物及其在药学上的应用 Download PDFInfo
- Publication number
- WO2022063317A1 WO2022063317A1 PCT/CN2021/121335 CN2021121335W WO2022063317A1 WO 2022063317 A1 WO2022063317 A1 WO 2022063317A1 CN 2021121335 W CN2021121335 W CN 2021121335W WO 2022063317 A1 WO2022063317 A1 WO 2022063317A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- reaction solution
- added
- reaction
- stirred
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 753
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- -1 tetrahydrooxazinyl Chemical group 0.000 claims description 99
- 238000002360 preparation method Methods 0.000 claims description 47
- 229910052757 nitrogen Inorganic materials 0.000 claims description 34
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 27
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000003386 piperidinyl group Chemical group 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000000532 dioxanyl group Chemical group 0.000 claims description 4
- 125000005883 dithianyl group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 647
- 239000000243 solution Substances 0.000 description 572
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 458
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 297
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 281
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 276
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 206
- 238000003786 synthesis reaction Methods 0.000 description 205
- 230000015572 biosynthetic process Effects 0.000 description 204
- 235000019439 ethyl acetate Nutrition 0.000 description 153
- 150000004675 formic acid derivatives Chemical class 0.000 description 128
- 239000012074 organic phase Substances 0.000 description 122
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 119
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 106
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 106
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 103
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 96
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 95
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 92
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 90
- 238000010898 silica gel chromatography Methods 0.000 description 89
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 87
- 238000010828 elution Methods 0.000 description 75
- 238000005481 NMR spectroscopy Methods 0.000 description 72
- 239000003480 eluent Substances 0.000 description 67
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 63
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 58
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 56
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 55
- 239000003208 petroleum Substances 0.000 description 53
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- 238000000034 method Methods 0.000 description 47
- 229920006395 saturated elastomer Polymers 0.000 description 44
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 40
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- 239000012071 phase Substances 0.000 description 38
- 229910000033 sodium borohydride Inorganic materials 0.000 description 35
- 239000012279 sodium borohydride Substances 0.000 description 35
- 239000007787 solid Substances 0.000 description 34
- 238000004128 high performance liquid chromatography Methods 0.000 description 33
- 238000003756 stirring Methods 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- 239000012043 crude product Substances 0.000 description 31
- AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 description 30
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 29
- 235000019253 formic acid Nutrition 0.000 description 29
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 29
- 239000012488 sample solution Substances 0.000 description 28
- 239000012528 membrane Substances 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 23
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 21
- YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 description 21
- 235000019270 ammonium chloride Nutrition 0.000 description 20
- 230000014759 maintenance of location Effects 0.000 description 20
- 235000017557 sodium bicarbonate Nutrition 0.000 description 20
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 20
- 229910000029 sodium carbonate Inorganic materials 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- 238000000926 separation method Methods 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 238000010791 quenching Methods 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 15
- 239000002994 raw material Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 239000012312 sodium hydride Substances 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 description 10
- 239000001569 carbon dioxide Substances 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000012065 filter cake Substances 0.000 description 10
- 238000004811 liquid chromatography Methods 0.000 description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 9
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 230000001270 agonistic effect Effects 0.000 description 8
- 229940126543 compound 14 Drugs 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 7
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 7
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 7
- 229910000838 Al alloy Inorganic materials 0.000 description 7
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 7
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 7
- 102000017926 CHRM2 Human genes 0.000 description 7
- 102000017925 CHRM3 Human genes 0.000 description 7
- 101150060249 CHRM3 gene Proteins 0.000 description 7
- 101150012960 Chrm2 gene Proteins 0.000 description 7
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 7
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 229940125758 compound 15 Drugs 0.000 description 7
- 229940125961 compound 24 Drugs 0.000 description 7
- 229940125878 compound 36 Drugs 0.000 description 7
- 229940127573 compound 38 Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 7
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 6
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 6
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 6
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 6
- IOQORVDNYPOZPL-VQTJNVASSA-N (5S,6R)-5-(4-chlorophenyl)-6-cyclopropyl-3-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-5,6-dihydro-2H-1,2,4-oxadiazine Chemical compound ClC1=CC=C(C=C1)[C@@H]1NC(=NO[C@@H]1C1CC1)C1=NC(=C(C=C1)N1C=NC(=C1)C)OC IOQORVDNYPOZPL-VQTJNVASSA-N 0.000 description 6
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 6
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229940126639 Compound 33 Drugs 0.000 description 6
- 229940127007 Compound 39 Drugs 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 6
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 6
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 6
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 229940126142 compound 16 Drugs 0.000 description 6
- 229940125846 compound 25 Drugs 0.000 description 6
- 229940127204 compound 29 Drugs 0.000 description 6
- 229940125807 compound 37 Drugs 0.000 description 6
- 229940126540 compound 41 Drugs 0.000 description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 238000004237 preparative chromatography Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940126086 compound 21 Drugs 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 5
- 239000012414 tert-butyl nitrite Substances 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- 108091006065 Gs proteins Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- MXZNUGFCDVAXLG-CHWSQXEVSA-N [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@@H](NC(=O)c1ccncc1)C(=O)N1CCC[C@@H]1B(O)O MXZNUGFCDVAXLG-CHWSQXEVSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 229940125810 compound 20 Drugs 0.000 description 4
- 229940126208 compound 22 Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- ACDLOOGOFKSUPO-UHFFFAOYSA-N 2-bromo-5-methylthiophene Chemical compound CC1=CC=C(Br)S1 ACDLOOGOFKSUPO-UHFFFAOYSA-N 0.000 description 3
- RVCTZBRMQZWVDA-UHFFFAOYSA-N 2-bromo-5-phenylthiophene Chemical compound S1C(Br)=CC=C1C1=CC=CC=C1 RVCTZBRMQZWVDA-UHFFFAOYSA-N 0.000 description 3
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 3
- 229940045803 cuprous chloride Drugs 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 3
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 2
- ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 description 2
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 description 2
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 2
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 2
- YQYBUJYBXOVWQW-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3,4-dihydro-1H-isoquinolin-2-yl)methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1CC2=CC=CC=C2CC1 YQYBUJYBXOVWQW-UHFFFAOYSA-N 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940112669 cuprous oxide Drugs 0.000 description 2
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- LSCYTCMNCWMCQE-UHFFFAOYSA-N n-methylpyridin-4-amine Chemical compound CNC1=CC=NC=C1 LSCYTCMNCWMCQE-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 229960001922 sodium perborate Drugs 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- ZOWSJJBOQDKOHI-UHFFFAOYSA-N 2,2,2-trifluoroethyl acetate Chemical compound CC(=O)OCC(F)(F)F ZOWSJJBOQDKOHI-UHFFFAOYSA-N 0.000 description 1
- UJORPFQWUKFXIE-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4h-cyclopenta[c]pyrazol-3-yl]-5-methoxy-n-pyridin-4-ylpyrimidin-4-amine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C(CCC2)=C2C(C=2N=C(NC=3C=CN=CC=3)C(OC)=CN=2)=N1 UJORPFQWUKFXIE-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MROVZCRMXJZHCN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxyethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCO)C=CC=1 MROVZCRMXJZHCN-UHFFFAOYSA-N 0.000 description 1
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ZNKWRAKPQQZLNX-ZDQHWEPJSA-N CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc12)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 ZNKWRAKPQQZLNX-ZDQHWEPJSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101100490572 Homo sapiens ADRB1 gene Proteins 0.000 description 1
- 101100378542 Homo sapiens ADRB2 gene Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000989747 Maba Species 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present application relates to a fused tricyclic derivative and its pharmaceutical application, in particular to a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.
- a single molecule with dual activity on muscarinic M3 and ⁇ 2 adrenergic receptors (MABA) is more likely to demonstrate the synergistic effect of the drug on the target than the two-component compound combination with consistent pharmacokinetic properties.
- MABA muscarinic M3 and ⁇ 2 adrenergic receptors
- Relevant advantages will also be shown in terms of formulation. It will also become easier to co-formulate with other therapeutic agents such as inhaled glucocorticoids to create triple therapy combinations. Therefore, novel drugs that have both ⁇ 2 receptor agonist and muscarinic receptor antagonist activities and are suitable for the treatment of respiratory diseases such as asthma and COPD have high clinical value and significance.
- R 1 is selected from H, halogen, C 1-4 alkyl, or phenyl;
- Each R 2 is independently selected from H, halogen, or C 1-4 alkyl
- n is selected from 1 or 2;
- T 1 is selected from a single bond, -NH-, or -N(CH 3 )-;
- L 1 is selected from a single bond or -CH 2 -;
- Ring A is selected from the following groups optionally substituted with 1 or 2 R b : C 4-6 cycloalkenyl, 4-6 membered heterocycloalkenyl, 5-6 membered heteroaryl, or phenyl;
- each R b is independently selected from -F, -Cl, -Br , -I, -CH3 , or -CH2CH3 ;
- Ring B is selected from cyclopentyl, cyclohexyl, or 6-10-membered heterocycloalkyl, and the 6-10-membered heterocycloalkyl is optionally substituted by one R a ;
- Ra is selected from -F, -Cl, methyl, -OH, or -CN;
- hetero of the "6-10 membered heterocycloalkyl” contains 1, 2 or 3 heteroatoms or heteroatoms independently selected from O, S, NH and N, wherein the nitrogen atom is optionally halomethane Quaternized.
- R1 is selected from H, -Cl, -Br, methyl, tert-butyl, or phenyl.
- R 1 is selected from H, halogen, or C 1-4 alkyl.
- R1 is selected from H, -Cl, -Br, methyl, or tert-butyl.
- each R 2 is independently selected from H, -Cl, -Br, methyl, or tert-butyl.
- each R 2 is independently selected from H, halogen, or C 1-4 alkyl.
- both R 1 and R 2 are H.
- T1 is selected from a single bond or -N( CH3 )-.
- ring B is selected from cyclohexyl, or 6-10-membered heterocycloalkyl, and the 6-10-membered heterocycloalkyl is optionally substituted with 1 R a .
- the above-mentioned ring B is selected from cyclopentyl, cyclohexyl, or the following groups optionally substituted by one R a : piperidinyl, piperazinyl, morpholinyl, dioxanyl, Dithianyl, tetrahydrooxazinyl, tetrahydrothiazinyl, hexahydropyridazinyl, homopiperazinyl, homopiperidinyl, dioxepanyl,
- the above-mentioned ring B is selected from cyclohexyl, or the following groups optionally substituted by 1 R a : piperidinyl, piperazinyl,
- the above-mentioned ring B is selected from cyclohexyl, or the following groups optionally substituted by 1 R a :
- the above-mentioned ring B is selected from cyclohexyl. In some aspects of the present application, the above-mentioned ring B is selected from
- the above-mentioned ring B is selected from
- the above-mentioned ring B is selected from
- R b is independently selected from -F, -Cl, -Br, -I, or -CH3 .
- R b is selected from -CH 3 .
- Ra is selected from -F, -CH3 , -OH, or -CN.
- Ra is selected from -CH3 , or -OH.
- the above-mentioned ring A is selected from C 4-6 cycloalkenyl, 4-6 membered heterocycloalkenyl, 5-6 membered heteroaryl, or phenyl, the C 4-6 cycloalkenyl, 4-6 membered heterocycloalkenyl and 5-6 membered heteroaryl are optionally substituted with 1 or 2 R b .
- the above ring A is selected from the following groups optionally substituted with 1 or 2 R b : pyrrolyl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or phenyl.
- the above ring A is selected from the following groups optionally substituted with 1 or 2 R b : pyrazolyl, or phenyl.
- the above-mentioned ring A is selected from
- the above-mentioned ring A is selected from
- the above-mentioned ring A is selected from
- the above-mentioned ring A is selected from
- the heterocycloalkyl, heterocycloalkenyl, and heteroaryl groups contain 1, 2 or 3 heteroatoms selected from N, O or S.
- heterocycloalkyl, heterocycloalkenyl, and heteroaryl groups contain 1 or 2 heteroatoms selected from N or O.
- the 6-10 membered heterocycloalkyl includes a monocyclic, spiro or bridged ring.
- the 6-10 membered heterocycloalkyl includes a monocyclic or spirocyclic ring.
- the above compounds are selected from the structures shown in (III-1), (III-2), (III-3), (IV-1), (IV-2) and (V-1). ,
- R 1 , R 2 , T 1 , n, L 1 and Ring B are as defined herein.
- R 1 is selected from H, halogen and C 1-4 alkyl
- each R 2 is independently selected from H, halogen and C 1-4 alkyl
- n is selected from 1 and 2;
- T 1 is selected from single bond, -NH- and -N(CH 3 )-;
- Ring A is selected from and phenyl
- Ring B is selected from cyclohexyl, piperidinyl,
- R 1 , R 2 , T 1 , n and Ring B are as defined herein.
- R 1 is selected from H, -Cl, -Br and tert-butyl.
- each of the above R 2 is independently selected from H, -Cl, -Br and tert-butyl.
- the present application also provides a pharmaceutical composition
- a pharmaceutical composition comprising the above-mentioned compound or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition may also contain pharmaceutically acceptable excipients.
- the present application also provides the use of the above-mentioned compound or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- the application also provides the use of the above-mentioned compound or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition in preparing a medicine for treating chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- the present application also provides the use of the above-mentioned compound or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition for treating chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- the present application also provides the above-mentioned compound or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition for the treatment of chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- the present application also provides a method for treating chronic obstructive pulmonary disease (COPD), comprising administering to an individual in need thereof a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition.
- COPD chronic obstructive pulmonary disease
- the compound of the present application has good dual activities of muscarinic receptor M3 antagonism and ⁇ 2-adrenergic receptor agonism, and has a certain selectivity relative to the activity of ⁇ 1.
- muscarinic receptor M3 antagonism and ⁇ 2-adrenergic receptor agonism
- ⁇ 2-adrenergic receptor agonism Compared with the reference compound AZD8871, it has a faster clearance rate after intravenous administration, longer half-life, higher exposure, and higher bioavailability after nebulized needle tracheal administration.
- the term "pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissue , without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- salts refers to salts of the compounds of the present application, prepared from compounds with specific substituents discovered herein and relatively non-toxic acids or bases.
- base addition salts can be obtained by contacting such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent.
- acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent.
- Certain specific compounds of the present application contain both basic and acidic functional groups and thus can be converted into either base or acid addition salts.
- the pharmaceutically acceptable salts of the present application can be synthesized from the parent compound containing acid or base by conventional chemical methods. Generally, such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of the two.
- the term “isomer” is intended to include geometric isomers, cis-trans isomers, stereoisomers, enantiomers, optical isomers, diastereomers and tautomers isomer.
- the compounds of the present application may exist in specific geometric or stereoisomeric forms.
- This application contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and racemic mixtures thereof and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which belong to this within the scope of the application.
- Additional asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers, as well as mixtures thereof, are included within the scope of this application.
- enantiomers or “optical isomers” refer to stereoisomers that are mirror images of each other.
- cis-trans isomer or “geometric isomer” result from the inability to rotate freely due to double bonds or single bonds to ring carbon atoms.
- diastereomer refers to a stereoisomer in which the molecule has two or more chiral centers and the molecules are in a non-mirror-image relationship.
- the terms “enriched in one isomer”, “enriched in isomers”, “enriched in one enantiomer” or “enriched in one enantiomer” refer to one of the isomers or pairs
- the enantiomer content is less than 100%, and the isomer or enantiomer content is greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or Greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.
- isomeric excess or “enantiomeric excess” refer to the difference between two isomers or relative percentages of two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomeric excess (ee value) is 80% .
- Optically active (R)- and (S)-isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If an enantiomer of a compound of the present application is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting mixture of diastereomers is separated and the auxiliary group is cleaved to provide pure desired enantiomer.
- a diastereomeric salt is formed with an appropriate optically active acid or base, followed by conventional methods known in the art
- the diastereoisomers were resolved and the pure enantiomers recovered.
- separation of enantiomers and diastereomers is usually accomplished by the use of chromatography employing a chiral stationary phase, optionally in combination with chemical derivatization (eg, from amines to amino groups) formate).
- the compounds of the present application may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compounds.
- compounds can be labeled with radioisotopes, such as tritium ( 3 H), iodine-125 ( 125 I) or C-14 ( 14 C).
- deuterated drugs can be formed by replacing hydrogen with deuterium, and the bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs can reduce toxic side effects and increase drug stability. , enhance the efficacy, prolong the biological half-life of drugs and other advantages. All alterations in the isotopic composition of the compounds of the present application, whether radioactive or not, are included within the scope of the present application.
- C 1-4 alkyl is used to denote a straight or branched chain saturated hydrocarbon group consisting of 1 to 4 carbon atoms.
- the C 1-4 alkyl includes C 1-2 , C 1-3 and C 2-3 alkyl, etc.; it can be monovalent (such as methyl), divalent (such as methylene) or polyvalent (such as methine).
- Examples of C 1-4 alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl , s-butyl and t-butyl) and so on.
- C 4-6 cycloalkyl means a saturated cyclic hydrocarbon group consisting of 4 to 6 carbon atoms, which are monocyclic and bicyclic ring systems, said C 4-6 cycloalkyl group includes C 4-5 and C 5-6 cycloalkyl and the like; it may be monovalent, divalent or polyvalent.
- Examples of C4-6 cycloalkyl include, but are not limited to, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- C 4-6 cycloalkenyl refers to an incompletely saturated cyclic hydrocarbon group consisting of 4 to 6 carbon atoms, which is a monocyclic and bicyclic ring system.
- the C 4-6 cycloalkenyl includes C 4-5 and C 5-6 cycloalkenyl and the like; it may be monovalent, divalent or polyvalent.
- Non-limiting examples of C 4-6 cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
- 4-6 membered heterocycloalkyl by itself or in combination with other terms denotes a saturated cyclic group consisting of 4 to 6 ring atoms, respectively, of which 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, where the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (ie, NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein bicyclic ring systems include spiro, paracyclic and bridged rings.
- a heteroatom may occupy the position of attachment of the heterocycloalkyl to the remainder of the molecule.
- the 4-6 membered heterocycloalkyl includes 5-6 membered, 4 membered, 5 membered and 6 membered heterocycloalkyl and the like.
- 4-6 membered heterocycloalkyl examples include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl ( Including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2- piperidinyl and 3-piperidyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), Dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl,
- 4-6 membered heterocycloalkenyl refers to a partially unsaturated (but not fully unsaturated heteroaryl) non-aromatic ring consisting of 4 to 6 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e. NO and S(O) p , where p is 1 or 2). It includes monocyclic and bicyclic ring systems, wherein bicyclic ring systems include spiro, paracyclic and bridged rings.
- a heteroatom may occupy the position of attachment of the heterocycloalkyl to the remainder of the molecule.
- the 4-6 membered heterocyclyl group includes 4-membered, 5-membered and 6-membered heterocyclyl groups and the like.
- Examples of 4-6 membered heterocycloalkenyl groups include, but are not limited to, dihydropyrrolyl, dihydrofuranyl, dihydropyridyl, tetrahydropyridyl, dihydropyranyl, and the like.
- the terms “5-6 membered heteroaryl” and “5-6 membered heteroaryl” are used interchangeably in this application, and the term “5-6 membered heteroaryl” means from 5 to 6 ring atoms It is composed of a monocyclic group with a conjugated ⁇ electron system, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. Where the nitrogen atom is optionally quaternized, the nitrogen and sulfur heteroatoms may be optionally oxidized (ie, NO and S(O) p , p is 1 or 2).
- a 5-6 membered heteroaryl group can be attached to the remainder of the molecule through a heteroatom or a carbon atom.
- the 5-6 membered heteroaryl groups include 5- and 6-membered heteroaryl groups.
- Examples of the 5-6 membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrrolyl, etc.) azolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5- oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1, 2,4
- 6-10 membered heterocycloalkyl by itself or in combination with other terms denotes a saturated cyclic group consisting of 6 to 10 ring atoms, respectively, of which 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, where the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (ie, NO and S(O) p , p is 1 or 2). It includes monocyclic, bicyclic and tricyclic rings, wherein bicyclic and tricyclic rings include spiro, paracyclic and bridged rings.
- a heteroatom may occupy the position of attachment of the heterocycloalkyl to the remainder of the molecule.
- the 6-10 membered heterocycloalkyl includes 6-7 membered, 6-8 membered, 6-9 membered, 6 membered, 7 membered, 8 membered, 9 membered and 10 membered heterocycloalkyl and the like.
- 6-10 membered heterocycloalkyl examples include, but are not limited to, piperidinyl (including 1-piperidinyl, 2-piperidinyl, and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl, and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1, 2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl, homopiperidinyl or dioxepanyl and the like.
- halogen or halogen by itself or as part of another substituent means a fluorine, chlorine, bromine or iodine atom.
- the carbon atoms with "*" are chiral carbon atoms, which exist as (R) or (S) single enantiomer or enriched in one enantiomer.
- substituted means that any one or more hydrogen atoms on a specified atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence of the specified atom is normal and the substituted compound is stable.
- oxygen it means that two hydrogen atoms are substituted. Oxygen substitution does not occur on aromatic groups.
- optionally substituted means that it may or may not be substituted, and unless otherwise specified, the type and number of substituents may be arbitrary on a chemically achievable basis.
- any variable eg, R
- its definition in each case is independent.
- the group may optionally be substituted with up to two Rs, with independent options for R in each case.
- combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
- linking group When the number of a linking group is 0, such as -(CRR) 0 -, it means that the linking group is a single bond.
- substituent R can be substituted at any position on cyclohexyl or cyclohexadiene.
- substituents do not specify through which atom it is attached to the substituted group, such substituents may be bonded through any of its atoms, for example, pyridyl as a substituent may be through any one of the pyridine rings. The carbon atom is attached to the substituted group.
- the direction of attachment is arbitrary, for example,
- the linking group L in the middle is -MW-, at this time -MW- can connect ring A and ring B in the same direction as the reading order from left to right. It is also possible to connect ring A and ring B in the opposite direction to the reading order from left to right.
- Combinations of the linking groups, substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
- any one or more sites in the group can be linked to other groups by chemical bonds.
- connection method of the chemical bond is not positioned and there is an H atom at the connectable site, when the chemical bond is connected, the number of H atoms at the site will decrease correspondingly with the number of chemical bonds connected to the corresponding valence. the group.
- the chemical bond connecting the site to other groups can be represented by straight solid line bonds straight dotted key or wavy lines Express.
- a straight solid bond in -OCH 3 indicates that it is connected to other groups through the oxygen atom in this group;
- the straight dashed bond in the group indicates that it is connected to other groups through the two ends of the nitrogen atom in the group;
- the wavy line in the phenyl group indicates that it is connected to other groups through the 1 and 2 carbon atoms in the phenyl group;
- the number of atoms in a ring is generally defined as the number of ring members, eg, "5-7 membered ring” refers to a “ring” of 5-7 atoms arranged around it.
- protecting group includes, but is not limited to, "amino protecting group", “hydroxy protecting group” or “thiol protecting group”.
- amino protecting group refers to a protecting group suitable for preventing side reactions at the amino nitrogen position.
- Representative amino protecting groups include, but are not limited to: formyl; acyl groups, such as alkanoyl groups (eg, acetyl, trichloroacetyl, or trifluoroacetyl); alkoxycarbonyl groups, such as tert-butoxycarbonyl (Boc) ; Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); Arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di -(4'-Methoxyphenyl)methyl; silyl groups such as trimethylsilyl (TMS) and tert-
- hydroxy protecting group refers to a protecting group suitable for preventing hydroxyl side reactions.
- Representative hydroxy protecting groups include, but are not limited to: alkyl groups such as methyl, ethyl and tert-butyl; acyl groups such as alkanoyl (eg acetyl); arylmethyl groups such as benzyl (Bn), p-methyl Oxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl groups such as trimethylsilyl (TMS) and tert-butyl Dimethylsilyl (TBS) and the like.
- alkyl groups such as methyl, ethyl and tert-butyl
- acyl groups such as alkanoyl (eg acetyl)
- arylmethyl groups such as benzyl (Bn), p-methyl Oxybenzyl (PMB), 9-fluorenyl
- the compounds of the present application can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by their combination with other chemical synthesis methods, and those well known to those skilled in the art Equivalent to alternatives, preferred embodiments include but are not limited to the examples of the present application.
- the structures of the compounds of the present application can be confirmed by conventional methods well known to those skilled in the art. If the present application relates to the absolute configuration of the compounds, the absolute configuration can be confirmed by conventional technical means in the art. For example, single crystal X-ray diffraction method (SXRD), the cultured single crystal is collected by Bruker D8 venture diffractometer, the light source is CuK ⁇ radiation, and the scanning mode is: After scanning and collecting relevant data, the crystal structure was further analyzed by the direct method (Shelxs97), and the absolute configuration could be confirmed.
- SXRD single crystal X-ray diffraction method
- the cultured single crystal is collected by Bruker D8 venture diffractometer
- the light source is CuK ⁇ radiation
- the scanning mode is: After scanning and collecting relevant data, the crystal structure was further analyzed by the direct method (Shelxs97), and the absolute configuration could be confirmed.
- the solvent used in the present invention is commercially available.
- the following acronyms are used in this application: aq. and H 2 O for water; eq for equivalents, equivalents; Boc for tert-butoxycarbonyl; PE for petroleum ether; ACN for acetonitrile; EtOAc for ethyl acetate; EtOH for ethanol ; MeOH stands for methanol; TBS stands for tert-butyldimethylsilyl; HPLC stands for high performance liquid chromatography; LCMS stands for liquid chromatography-mass spectrometry; rt stands for room temperature; mp stands for melting point; mM stands for millimoles per liter; mmol stands for millimoles; ⁇ mol stands for micromoles; HNMR stands for proton nuclear magnetic resonance spectroscopy; MS stands for mass spectrometry; min stands for minutes;
- reaction solution was concentrated to dryness, 10 mL of water was added, and the mixture was extracted with dichloromethane (20 mL ⁇ 2). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness under reduced pressure, and separated and purified by flash silica gel column chromatography (eluent: methanol/dichloromethane, 0-10%) to obtain Compounds 1-16.
- Lithium tetrahydroaluminum (9.70 g) was dissolved in tetrahydrofuran (500 mL), and compound 5-4-1 (11.0 g) was added in portions at 0°C. The temperature of the reaction solution was raised to 75°C and the reaction was stirred for 14 hours. At 0°C, water (10 mL) was carefully and slowly added dropwise to the reaction solution to quench the reaction, then 4N aqueous sodium hydroxide solution (10 mL) was added, and finally water (20 mL) was added, and filtered. Dry over aqueous sodium sulfate, filter, and concentrate under reduced pressure. The residue was slurried with petroleum ether (80 mL) at room temperature for 20 minutes, filtered, and concentrated under reduced pressure to obtain compound 5-4-2.
- Step 7 Preparation of Compounds 5-7A and 5-7B
- the retention time of compound 5-7A in the high-performance chiral liquid column is: 5.656min.
- Step 8 Synthesis of Compounds 5-8
- Mobile phase system acetonitrile/water (containing 0.225% formic acid).
- Gradient elution method acetonitrile gradient elution from 15% to 35%, elution time 7 minutes) separation to obtain the methyl ester of compound 5 acid salt.
- the formate of compound 6 is prepared with reference to the synthetic route of the formate of compound 5, using compound 5-7B as a raw material through a 2-step reaction.
- Mobile phase system acetonitrile/water (containing 0.075% trifluoroacetic acid); gradient elution method: acetonitrile gradient elution from 28% to 58%, elution time 8 minutes) separation to obtain three compounds of compound 7 Fluoroacetate.
- reaction was quenched by adding saturated aqueous sodium bicarbonate solution (15 mL), and extracted with ethyl acetate (30 mL ⁇ 3). The organic phases were combined, washed with water (20 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude compound 8-5.
- reaction solution was concentrated under reduced pressure, and the residue was subjected to high performance liquid chromatography (column type: Welch Xtimate C18, length*inner diameter: 100*40mm*3 ⁇ m; preparation method: the crude product was dissolved in dimethyl sulfoxide, and filtered with a 0.45 ⁇ m filter membrane, Prepare a sample solution; mobile phase system: acetonitrile/water (containing 0.75% trifluoroacetic acid); gradient elution method: acetonitrile gradient elution from 23% to 53%, elution time 8min) separation and purification to obtain three compounds of compound 8. Fluoroacetate.
- the trifluoroacetate salt of compound 9 refers to the synthetic route of the trifluoroacetate salt of compound 8: compound 8-2B is used as the raw material, and it is prepared through 4 steps of reaction.
- Preparation method the crude product was dissolved in dimethyl sulfoxide, and filtered through a 0.45 ⁇ m filter membrane to prepare a sample solution; mobile phase system: acetonitrile/water (containing 0.075% trifluoroacetic acid); gradient elution method: acetonitrile was washed with a 30% gradient to 60%, elution time 8 minutes), separation and purification to obtain the trifluoroacetate salt of compound 10.
- Compound 13-2 (520 mg) was separated and purified by chiral liquid chromatography to obtain compound 13-2a and compound 13-2b.
- SFC separation method chromatographic column (DAICEL CHIRALCEL IC (250mm ⁇ 30mm, 10 ⁇ m)); mobile phase: A: carbon dioxide; B: 40% ⁇ 40% ethanol (including 0.1% ammonia water); flow rate: 70mL/min; column temperature: 40°C.
- the reaction was quenched by adding saturated aqueous sodium bicarbonate solution (30 mL), and extracted with ethyl acetate (30 mL ⁇ 3). The organic phases were combined, washed with brine (20 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude compound 13-5.
- the synthesis of the trifluoroacetate salt of compound 14 refers to the synthetic route of the trifluoroacetate salt of compound 13: using compound 13-2b as a raw material, it is prepared through 4 steps of reactions, and the details are shown in steps 8-11.
- Mobile phase system acetonitrile/water (containing 0.075% trifluoroacetic acid); gradient elution method: acetonitrile gradient elution from 22% to 52%, elution time 8 minutes) to obtain three compounds of compound 14 Fluoroacetate.
- Compound 15-1 (243 mg) was separated and purified by chiral liquid chromatography to obtain compound 15-1a and compound 15-1b.
- SFC separation method chromatographic column (DAICEL CHIRALPAK AD (250mm ⁇ 30mm, 10 ⁇ m)); mobile phase: A: carbon dioxide; B: 55% ⁇ 55% ethanol (containing 0.1% ammonia water); flow rate: 70mL/min; column temperature: 40°C.
- the reaction was quenched by adding saturated aqueous sodium bicarbonate solution (30 mL), and extracted with ethyl acetate (30 mL ⁇ 3). The organic phases were combined, washed with brine (20 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude compound 15-4.
- reaction solution was concentrated under reduced pressure, and the residue was subjected to high performance liquid chromatography (column type: Welch Xtimate C18, length*inner diameter: 100mm*40mm, 3 ⁇ m; preparation method: the crude product was dissolved in dimethyl sulfoxide, and filtered with a 0.45 ⁇ m filter membrane, Prepare a sample solution.
- Mobile phase system acetonitrile/water (containing 0.075% trifluoroacetic acid); gradient elution method: acetonitrile gradient elution from 25% to 55%, elution time 8 minutes) to separate the trifluoro compound of compound 15 acetate.
- the synthesis of the trifluoroacetate salt of compound 16 refers to the synthetic route of the trifluoroacetate salt of compound 15: compound 15-1b is used as the raw material, and it is prepared through 4 steps of reaction.
- reaction solution was heated to 0°C, quenched with saturated aqueous ammonium chloride solution (10 mL), extracted with ethyl acetate (15 mL ⁇ 2), washed with saturated brine (20 mL), and the organic phase was washed with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was separated and purified by flash silica gel column chromatography (eluent: ethyl acetate/petroleum ether, 0-25%) to obtain compound 17-2.
- Step 3 Chiral resolution to obtain compounds 17-2a, 17-2b
- Compound 17-2 was separated and purified by chiral liquid chromatography to obtain compound 17-2a and compound 17-2b.
- SFC separation method chromatographic column: DAICEL CHIRALPAK AD 250mm ⁇ 30mm, 10 ⁇ m; mobile phase: A: carbon dioxide; B: ethanol (containing 0.1% ammonia water); flow rate: 70mL/min; column temperature: 40°C.
- the synthesis of the formate salt of compound 18 refers to the synthetic route of the formate salt of compound 17: compound 17-2b is used as the raw material, and it is prepared through 4 steps of reaction.
- reaction solution was warmed to 0°C, quenched with saturated aqueous ammonium chloride solution (10 mL), extracted with ethyl acetate (15 mL ⁇ 2), washed with saturated brine (30 mL), and the organic phase was washed with anhydrous sodium sulfate and concentrated under reduced pressure.
- the residue was separated and purified by flash silica gel column chromatography (eluent: ethyl acetate/petroleum ether, 0-25%) to obtain compound 20-1.
- Step 2 Preparation of Compounds 20-1A, 20-1B
- Compound 20-1 was separated and purified by chiral liquid chromatography to obtain compound 20-1A and compound 20-1B.
- SFC separation method chromatographic column (DAICEL CHIRALPAK OJ 250mm ⁇ 30mm, 10 ⁇ m); mobile phase: A: carbon dioxide; B: ethanol (containing 0.1% ammonia water); flow rate: 80mL/min; column temperature: 40°C.
- the synthesis of the formate salt of compound 21 refers to the synthetic route of the formate salt of compound 20: compound 20-1B is used as the raw material, and it is prepared through 4 steps of reaction.
- reaction solution was warmed to 0°C, quenched with saturated aqueous ammonium chloride solution (20 mL), extracted with ethyl acetate (30 mL ⁇ 2), washed with saturated brine (50 mL), and the organic phase was washed with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was separated and purified by flash silica gel column chromatography (eluent: ethyl acetate/petroleum ether, 0-25%) to obtain compound 22-1.
- Compound 22-1 was separated and purified by chiral liquid chromatography to obtain compound 22-1a and compound 22-1b.
- SFC separation method chromatographic column (DAICEL CHIRALPAK AD 250mm ⁇ 30mm, 10 ⁇ m); mobile phase: A: carbon dioxide; B: ethanol (containing 0.1% ammonia water); flow rate: 50mL/min; column temperature: 40°C.
- the synthesis of the formate salt of compound 23 refers to the synthetic route of the formate salt of compound 22: compound 22-1b is used as the raw material, and it is prepared through 4-step reaction.
- Compound 24-2 was separated and purified by chiral liquid chromatography to obtain compound 24-2A and compound 24-2B.
- SFC separation method chromatographic column (DAICEL CHIRALPAK AD 250mm ⁇ 30mm, 10 ⁇ m); mobile phase: A: carbon dioxide; B: ethanol (containing 0.1% ammonia water); flow rate: 70mL/min; column temperature: 40°C.
- the synthesis of the formate salt of compound 25 refers to the synthetic route of the formate salt of compound 24: compound 24-2B is used as the raw material, and it is prepared through 4 steps of reaction.
- Compound 26-2 (520 mg) was separated and purified by chiral liquid chromatography to obtain compound 26-2a and compound 26-2b.
- SFC separation method chromatographic column (DAICEL CHIRALCEL IC (250mm ⁇ 30mm, 10 ⁇ m)); mobile phase: A: carbon dioxide; B: 40% ⁇ 40% ethanol (including 0.1% ammonia water); flow rate: 70mL/min; column temperature: 40°C.
- the reaction was quenched by adding saturated aqueous sodium bicarbonate solution (30 mL), and extracted with ethyl acetate (30 mL ⁇ 3). The organic phases were combined, washed with water (20 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude compound 26-5.
- Mobile phase system acetonitrile/water (containing 0.075% trifluoroacetic acid); gradient elution method: acetonitrile gradient elution from 24% to 54%, elution time 8 minutes. Trifluoroethyl acetate of compound 26 is obtained acid salt.
- the synthesis of the trifluoroacetate salt of compound 27 refers to the synthetic route of the trifluoroacetate salt of compound 26: compound 26-2b is used as the raw material, and it is prepared through 4 steps of reaction.
- Compound 28-2 (453 mg) was separated and purified by chiral liquid chromatography to obtain compound 28-2a and compound 28-2b.
- SFC separation method chromatographic column (DAICEL CHIRALPAK AD (250mm ⁇ 30mm, 10 ⁇ m)); mobile phase: A: carbon dioxide; B: 50% ⁇ 50% ethanol (containing 0.1% ammonia water); flow rate: 70mL/min; column temperature: 40°C.
- the reaction was quenched by adding saturated aqueous sodium bicarbonate solution (30 mL), and extracted with ethyl acetate (30 mL ⁇ 3). The organic phases were combined, washed with brine (20 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude compound 28-5.
- Mobile phase system acetonitrile/water (containing 0.075% trifluoroacetic acid); gradient elution method: acetonitrile gradient elution from 22% to 52%, elution time 8 minutes) to separate the trifluoro compound of compound 28 acetate.
- reaction solution was heated to 0°C, quenched with saturated aqueous ammonium chloride solution (100 mL), extracted with ethyl acetate (50 mL ⁇ 2), washed with saturated brine (50 mL), and the organic phase was washed with anhydrous sodium sulfate and concentrated under reduced pressure.
- the residue was separated and purified by flash silica gel column chromatography (eluent: ethyl acetate/petroleum ether, 0-10%), concentrated and then distilled off excess diethyl oxalate with oil pump at 70°C in a water bath to obtain compound 32 -1.
- reaction solution was warmed to 0°C, quenched with saturated aqueous ammonium chloride (20 mL), extracted with ethyl acetate (30 mL ⁇ 2), washed with saturated brine (50 mL), and the organic phase was washed with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was separated and purified by flash silica gel column chromatography (eluent: ethyl acetate/petroleum ether, 0-25%) to obtain compound 32-3.
- Acetic anhydride (8 mL) was placed in a reaction flask, and concentrated nitric acid (200 mg, concentration: 65%) was slowly added at -78°C. Then compound 33-3 (500 mg) was dissolved in acetic anhydride (5 mL) and slowly added dropwise to the reaction flask at -78°C. After the dropwise addition, the reaction solution was heated to 0°C and stirred for 1 hour. The reaction solution was slowly poured into ice water (100 mL) under stirring, and stirred for 10 minutes.
- the synthesis of the formate salt of compound 35 refers to the synthetic route of the formate salt of compound 34: compound 33-11 and 14-1 are used as raw materials, and the compound is prepared through three-step reaction.
- the synthesis of the formate salt of compound 37 refers to the synthetic route of the formate salt of compound 36: compound 36-12 and 14-1 are used as raw materials, and it is prepared through 3-step reaction.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
化合物编号 | EC 50(nM) | 化合物编号 | EC 50(nM) |
化合物1的三氟乙酸盐 | 84.54 | 化合物24的甲酸盐 | 155.1 |
化合物2的甲酸盐 | 157.1 | 化合物25的甲酸盐 | 193.3 |
化合物4的甲酸盐 | 303.9 | 化合物28的三氟乙酸盐 | 253.2 |
化合物5的甲酸盐 | 231.2 | 化合物29的三氟乙酸盐 | 432.2 |
化合物6的甲酸盐 | 277.6 | 化合物30的氢溴酸盐 | 94.9 |
化合物8的三氟乙酸盐 | 394.9 | 化合物32的甲酸盐 | 145.2 |
化合物9的三氟乙酸盐 | 696.3 | 化合物33的甲酸盐 | 53.13 |
化合物10的三氟乙酸盐 | 269.0 | 化合物34的甲酸盐 | 37.31 |
化合物11 | 33.7 | 化合物35的甲酸盐 | 55.58 |
化合物12的甲酸盐 | 127.2 | 化合物36的甲酸盐 | 50.49 |
化合物13的三氟乙酸盐 | 141.7 | 化合物37的甲酸盐 | 48.02 |
化合物14的三氟乙酸盐 | 127.2 | 化合物38的甲酸盐 | 337.6 |
化合物15的三氟乙酸盐 | 381.5 | 化合物39的甲酸盐 | 299.5 |
化合物16的三氟乙酸盐 | 276.1 | 化合物40的甲酸盐 | 56.67 |
化合物19的甲酸盐 | 1436 | 化合物41的甲酸盐 | 228.9 |
化合物21的甲酸盐 | 275.8 |
化合物编号 | EC 50(nM) | 化合物编号 | EC 50(nM) |
化合物1的三氟乙酸盐 | 3.472 | 化合物23的甲酸盐 | 16.77 |
化合物2的甲酸盐 | 0.8889 | 化合物24的甲酸盐 | 157.6 |
化合物4的甲酸盐 | 2.148 | 化合物25的甲酸盐 | 0.3881 |
化合物5的甲酸盐 | 2.635 | 化合物28的三氟乙酸盐 | 1.411 |
化合物6的甲酸盐 | 0.6244 | 化合物29的三氟乙酸盐 | 2.73 |
化合物8的三氟乙酸盐 | 1.618 | 化合物30的氢溴酸盐 | 1.714 |
化合物9的三氟乙酸盐 | 6.736 | 化合物32的甲酸盐 | 1.571 |
化合物10的三氟乙酸盐 | 1.357 | 化合物33的甲酸盐 | 0.7418 |
化合物11 | 1.122 | 化合物34的甲酸盐 | 0.4045 |
化合物12的甲酸盐 | 2.038 | 化合物35的甲酸盐 | 0.6714 |
化合物13的三氟乙酸盐 | 1.726 | 化合物36的甲酸盐 | 2.452 |
化合物14的三氟乙酸盐 | 1.397 | 化合物37的甲酸盐 | 1.933 |
化合物15的三氟乙酸盐 | 1.892 | 化合物38的甲酸盐 | 13.52 |
化合物16的三氟乙酸盐 | 2.161 | 化合物39的甲酸盐 | 21.9 |
化合物19的甲酸盐 | 5.139 | 化合物40的甲酸盐 | 2.802 |
化合物21的甲酸盐 | 2.113 | 化合物41的甲酸盐 | 13.76 |
化合物22的甲酸盐 | 20.82 |
化合物编号 | IC 50(nM) | 化合物编号 | IC 50(nM) |
化合物1的三氟乙酸盐 | 0.384 | 化合物21的甲酸盐 | 1.529 |
化合物2的甲酸盐 | 0.347 | 化合物24的甲酸盐 | 0.22 |
化合物3的甲酸盐 | 1.113 | 化合物25的甲酸盐 | 0.1787 |
化合物4的甲酸盐 | 0.3426 | 化合物28的三氟乙酸盐 | 0.136 |
化合物5的甲酸盐 | 13.78 | 化合物29的三氟乙酸盐 | 0.324 |
化合物6的甲酸盐 | 3.861 | 化合物30的氢溴酸盐 | 1.102 |
化合物7的三氟乙酸盐 | 5.572 | 化合物31的甲酸盐 | 0.6547 |
化合物8的三氟乙酸盐 | 2.77 | 化合物32的甲酸盐 | 1.197 |
化合物9的三氟乙酸盐 | 4.162 | 化合物33的甲酸盐 | 0.4938 |
化合物10的三氟乙酸盐 | 1.267 | 化合物34的甲酸盐 | 0.6572 |
化合物11 | 0.6384 | 化合物35的甲酸盐 | 0.2126 |
化合物13的三氟乙酸盐 | 0.6873 | 化合物36的甲酸盐 | 0.7921 |
化合物14的三氟乙酸盐 | 0.6606 | 化合物37的甲酸盐 | 0.8714 |
化合物15的三氟乙酸盐 | 0.1977 | 化合物38的甲酸盐 | 0.5552 |
化合物16的三氟乙酸盐 | 0.255 | 化合物39的甲酸盐 | 0.5333 |
化合物18的甲酸盐 | 9.361 | 化合物40的甲酸盐 | 0.3627 |
化合物19的甲酸盐 | 0.281 | 化合物41的甲酸盐 | 0.2013 |
化合物20的甲酸盐 | 31.07 |
化合物编号 | IC 50(nM) | 化合物编号 | IC 50(nM) |
化合物1的三氟乙酸盐 | 0.06196 | 化合物33的甲酸盐 | 0.1535 |
化合物13的三氟乙酸盐 | 0.2403 | 化合物34的甲酸盐 | 0.2481 |
化合物14的三氟乙酸盐 | 0.3754 | 化合物35的甲酸盐 | 0.5879 |
化合物15的三氟乙酸盐 | 0.1303 | 化合物36的甲酸盐 | 1.742 |
化合物16的三氟乙酸盐 | 0.104 | 化合物37的甲酸盐 | 2.012 |
化合物24的甲酸盐 | 0.014 | 化合物38的甲酸盐 | 0.8423 |
化合物25的甲酸盐 | 0.03 | 化合物39的甲酸盐 | 1.245 |
化合物28的三氟乙酸盐 | 0.0825 | 化合物40的甲酸盐 | 0.2282 |
化合物29的三氟乙酸盐 | 0.146 | 化合物41的甲酸盐 | 0.2676 |
化合物32的甲酸盐 | 0.8137 |
Claims (19)
- 式(III)所示化合物或其药学上可接受的盐,其中,R 1选自H、卤素、C 1-4烷基、或苯基;各R 2分别独立地选自H、卤素、或C 1-4烷基;或者,两个R 2及相连的噻吩环形成苯并噻吩;n选自1或2;T 1选自单键、-NH-、或-N(CH 3)-;L 1选自单键或-CH 2-;各R b分别独立地选自-F、-Cl、-Br、-I、-CH 3、或-CH 2CH 3;环B选自环戊基、环己基、或6~10元杂环烷基,所述6~10元杂环烷基任选被1个R a取代;R a选自-F、-Cl、甲基、-OH、或-CN;所述“6-10元杂环烷基”之“杂”包含1、2或3个独立选自O、S、NH和N的杂原子或杂原子团,其中氮原子任选地被卤代甲烷季铵化。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,R 1选自H、-Cl、-Br、甲基、叔丁基、或苯基。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,各R 2分别独立地选自H、-Cl、-Br、甲基或叔丁基。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,T 1选自单键或-N(CH 3)-。
- 根据权利要求1所述化合物或其药学上可接受的盐,其中,环B选自环己基、或6~10元杂环烷基,所述6~10元杂环烷基任选被1个R a取代。
- 根据权利要求1所述的化合物或其药学上可接受的盐,R a选自-F、-CH 3、-OH、或-CN。
- 根据权利要求1所述的化合物或其药学上可接受的盐,R b分别独立地选自-F、-Cl、-Br、-I、或-CH 3。
- 一种药物组合物,其包含权利要求1~17任意一项所述的化合物或其药学上可接受的盐;进一步地,所述药物组合物还可以包含药学上可接受的辅料。
- 根据权利要求1~17任意一项所述的化合物或其药学上可接受的盐或者权利要求18所述的药物组合物在制备治疗慢性阻塞性肺疾病的药物上的应用。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL301544A IL301544A (en) | 2020-09-28 | 2021-09-28 | Tricyclic substances and pharmaceutical preparations containing them |
CA3196035A CA3196035A1 (en) | 2020-09-28 | 2021-09-28 | Fused tricyclic derivative and pharmaceutical application thereof |
MX2023003280A MX2023003280A (es) | 2020-09-28 | 2021-09-28 | Derivado triciclico fusionado y aplicacion farmaceutica de este. |
US18/027,049 US20230322745A1 (en) | 2020-09-28 | 2021-09-28 | Fused tricyclic derivative and pharmaceutical application thereof |
CN202311389888.8A CN117534663A (zh) | 2020-09-28 | 2021-09-28 | 稠合的三并环衍生物及其在药学上的应用 |
KR1020237013537A KR20230079111A (ko) | 2020-09-28 | 2021-09-28 | 융합된 삼환계 유도체 및 이의 약학적 적용 |
AU2021348704A AU2021348704A1 (en) | 2020-09-28 | 2021-09-28 | Fused tricyclic derivative and pharmaceutical application thereof |
CN202180061646.9A CN116457357A (zh) | 2020-09-28 | 2021-09-28 | 稠合的三并环衍生物及其在药学上的应用 |
JP2023517873A JP2023542161A (ja) | 2020-09-28 | 2021-09-28 | 縮合三環式誘導体及び薬学上のその使用 |
EP21871686.8A EP4219485A1 (en) | 2020-09-28 | 2021-09-28 | Fused tricyclic derivative and pharmaceutical application thereof |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011040519.4 | 2020-09-28 | ||
CN202011040519 | 2020-09-28 | ||
CN202011615061.0 | 2020-12-30 | ||
CN202011615061 | 2020-12-30 | ||
CN202110357594 | 2021-04-01 | ||
CN202110357594.1 | 2021-04-01 | ||
CN202110648266 | 2021-06-10 | ||
CN202110648266.7 | 2021-06-10 | ||
CN202111094082 | 2021-09-17 | ||
CN202111094082.7 | 2021-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022063317A1 true WO2022063317A1 (zh) | 2022-03-31 |
Family
ID=80844500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/121335 WO2022063317A1 (zh) | 2020-09-28 | 2021-09-28 | 稠合的三并环衍生物及其在药学上的应用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230322745A1 (zh) |
EP (1) | EP4219485A1 (zh) |
JP (1) | JP2023542161A (zh) |
KR (1) | KR20230079111A (zh) |
CN (2) | CN116457357A (zh) |
AU (1) | AU2021348704A1 (zh) |
CA (1) | CA3196035A1 (zh) |
IL (1) | IL301544A (zh) |
MX (1) | MX2023003280A (zh) |
TW (1) | TWI814092B (zh) |
WO (1) | WO2022063317A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023179758A1 (zh) * | 2022-03-25 | 2023-09-28 | 正大天晴药业集团股份有限公司 | 稠合三并环衍生物或其可药用盐的结晶 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103998443A (zh) * | 2011-11-11 | 2014-08-20 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的新型环己胺衍生物 |
CN104024245A (zh) * | 2011-11-11 | 2014-09-03 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂和M3毒蕈碱拮抗剂活性的新型环己胺衍生物 |
CN105492027A (zh) * | 2013-07-25 | 2016-04-13 | 阿尔米雷尔有限公司 | 具有毒蕈碱受体拮抗体和β2肾上腺素能受体激动剂两种活性的2-氨基-1-羟乙基-8-羟基喹啉-2(1H)-酮衍生物的盐 |
WO2017012489A1 (zh) * | 2015-07-21 | 2017-01-26 | 四川海思科制药有限公司 | 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途 |
CN109928953A (zh) * | 2016-11-01 | 2019-06-25 | 四川海思科制药有限公司 | 一种羧酸酯衍生物及其在医药上的用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201835041A (zh) * | 2017-02-17 | 2018-10-01 | 印度商托仁特生技有限公司 | 具β-腎上腺素促效劑及抗蕈毒活性化合物 |
CN113544121A (zh) * | 2019-06-06 | 2021-10-22 | 中国医药研究开发中心有限公司 | 具有β2受体激动及M受体拮抗活性的杂环衍生物及其医药用途 |
-
2021
- 2021-09-28 EP EP21871686.8A patent/EP4219485A1/en active Pending
- 2021-09-28 MX MX2023003280A patent/MX2023003280A/es unknown
- 2021-09-28 IL IL301544A patent/IL301544A/en unknown
- 2021-09-28 KR KR1020237013537A patent/KR20230079111A/ko unknown
- 2021-09-28 WO PCT/CN2021/121335 patent/WO2022063317A1/zh active Application Filing
- 2021-09-28 CA CA3196035A patent/CA3196035A1/en active Pending
- 2021-09-28 CN CN202180061646.9A patent/CN116457357A/zh active Pending
- 2021-09-28 CN CN202311389888.8A patent/CN117534663A/zh active Pending
- 2021-09-28 AU AU2021348704A patent/AU2021348704A1/en active Pending
- 2021-09-28 TW TW110136121A patent/TWI814092B/zh active
- 2021-09-28 US US18/027,049 patent/US20230322745A1/en active Pending
- 2021-09-28 JP JP2023517873A patent/JP2023542161A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103998443A (zh) * | 2011-11-11 | 2014-08-20 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的新型环己胺衍生物 |
CN104024245A (zh) * | 2011-11-11 | 2014-09-03 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂和M3毒蕈碱拮抗剂活性的新型环己胺衍生物 |
CN105492027A (zh) * | 2013-07-25 | 2016-04-13 | 阿尔米雷尔有限公司 | 具有毒蕈碱受体拮抗体和β2肾上腺素能受体激动剂两种活性的2-氨基-1-羟乙基-8-羟基喹啉-2(1H)-酮衍生物的盐 |
WO2017012489A1 (zh) * | 2015-07-21 | 2017-01-26 | 四川海思科制药有限公司 | 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途 |
CN109928953A (zh) * | 2016-11-01 | 2019-06-25 | 四川海思科制药有限公司 | 一种羧酸酯衍生物及其在医药上的用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023179758A1 (zh) * | 2022-03-25 | 2023-09-28 | 正大天晴药业集团股份有限公司 | 稠合三并环衍生物或其可药用盐的结晶 |
Also Published As
Publication number | Publication date |
---|---|
MX2023003280A (es) | 2023-05-11 |
JP2023542161A (ja) | 2023-10-05 |
CN116457357A (zh) | 2023-07-18 |
KR20230079111A (ko) | 2023-06-05 |
CN117534663A (zh) | 2024-02-09 |
TWI814092B (zh) | 2023-09-01 |
US20230322745A1 (en) | 2023-10-12 |
EP4219485A1 (en) | 2023-08-02 |
IL301544A (en) | 2023-05-01 |
AU2021348704A1 (en) | 2023-05-25 |
AU2021348704A9 (en) | 2024-06-13 |
CA3196035A1 (en) | 2022-03-31 |
TW202214612A (zh) | 2022-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6916968B1 (ja) | Glp−1受容体アゴニストおよびその使用 | |
CN115702156A (zh) | 吡啶酰胺类化合物 | |
JP7464920B2 (ja) | 免疫調節としての芳香環誘導体及びその製造方法と使用 | |
WO2008069242A1 (ja) | 新規2環性複素環化合物 | |
WO2021063404A1 (zh) | 作为pd-1/pd-l1小分子抑制剂的化合物及其应用 | |
WO2020052649A1 (zh) | 作为lsd1抑制剂的环丙胺类化合物及其应用 | |
CN114174282A (zh) | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 | |
WO2022117059A1 (zh) | 组织蛋白酶c小分子抑制剂及其医药用途 | |
WO2021058024A1 (zh) | Lsd1抑制剂 | |
WO2022063308A1 (zh) | 一类1,7-萘啶类化合物及其应用 | |
WO2023001069A1 (zh) | 大环酰胺类化合物及其应用 | |
TWI814092B (zh) | 稠合的三并環衍生物及其在藥學上的應用 | |
CN103508931A (zh) | 六氢并环戊二烯衍生物、其制备方法及其在医药上的应用 | |
JP2021529214A (ja) | キノリノピロリジン−2−オン系誘導化合物及びその使用 | |
JP2021510164A (ja) | Cxcr2アンタゴニスト | |
WO2022166721A1 (zh) | 含1,4-氧杂氮杂环庚烷的并环类衍生物 | |
JP2023538645A (ja) | ボロン酸化合物 | |
WO2021233133A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
TW202206082A (zh) | 一種肌醇衍生物及其用途 | |
JP2022521673A (ja) | Pd-l1免疫調整剤であるフルオロビニルベンズアミド化合物 | |
RU2769715C9 (ru) | Агонисты рецептора glp-1 и их применение | |
CN111868032B (zh) | 犬尿氨酸通路抑制剂 | |
WO2022228317A1 (zh) | 哌嗪衍生物及其应用 | |
WO2021098810A1 (zh) | 用作选择性雄激素受体调节剂的化合物 | |
WO2022247862A1 (zh) | 苯并螺杂环衍生物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21871686 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180061646.9 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2023517873 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3196035 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023005287 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20237013537 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021871686 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021871686 Country of ref document: EP Effective date: 20230428 |
|
ENP | Entry into the national phase |
Ref document number: 2021348704 Country of ref document: AU Date of ref document: 20210928 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112023005287 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230322 |